NCT03780894View on ClinicalTrials.gov

Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

January 11, 2021

Study Completion Date

January 11, 2022

Conditions

PolytraumaTraumatic Hemorrhage

Interventions

DRUG

Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]

Administration of 2 mg of FC together with RBC and TXA

BIOLOGICAL

Red blood cells concentrate

Administration of 2 red blood cells concentrates together with FC and TXA

DRUG

Tranexamic Acid

Administration of 1g of TXA together with FC and RBC

Trial Locations (1)

17007

Hospital Josep Trueta, Girona

All Listed Sponsors

lead

Banc de Sang i Teixits

OTHER

NCT03780894 - Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care. | Biotech Hunter | Biotech Hunter